Document is current

Article History

Received: 31 October 2022

Revised: 13 January 2023

Accepted: 16 January 2023

First Online: 7 February 2023

Compliance with ethical standards

:

: KK reports personal fees for lecture from Teijin Pharma, Fuji Pharma, Sanwa Kagaku, Pfizer, and Mochida Pharma, and research funding from Teijin Pharma, outside the submitted work. SK reports other support from Teijin Home Healthcare Limited and grants from Philips Respironics Goudou Kaisha, Teijin Pharma Limited, Daiichi Sankyo Company, Limited, and Chugai Pharmaceutical Company, Ltd. outside the submitted work. IH reports grants and personal fees from Sanwa Kagaku Kenkyusho Co., Ltd. and Fuji Yakuhin Co., Ltd., personal fees from Pfizer Japan, Inc., and grants from Sumitomo Dainippon Pharma Co., Ltd. and Teijin Pharma Limited outside the submitted work. KK reports grants from Teijin Pharma Limited and personal fees from Mitsubishi Tanabe Pharma Corporation outside the submitted work. YS reports grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labor and Welfare Scientific Research, and the Japan Agency for Medical Research and Development during the conduct of the study and grants and personal fees from Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Takeda Pharmaceutical Company Ltd., and Nippon Boehringer Ingelheim Co., Ltd., grants from Boston Scientific Japan K.K., Chugai Pharmaceutical Company, Ltd., Eisai Co., Ltd., Fuji Yakuhin Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Medtronic Japan Co., Ltd., Nihon Medi-Physics Co., Ltd., Shionogi & Co., Ltd., Teijin Pharma Limited, ZERIA Pharmaceutical Co., Ltd., and St. Jude Medical Japan Co., Ltd., grants, personal fees and other support from MSD K.K., and personal fees from Asahi Kasei Pharma Corporation, Bayer Holding Ltd., Kowa Pharmaceutical Co., Ltd., Novartis Pharma K. K., Taisho Toyama Pharmaceutical Co., Ltd., and Toa Eiyo Ltd. Outside the submitted work. The remaining authors have no competing interests to declare.